Relievant provides patients with low risk therapy that affords the ability to alleviate their back pain.
Relievant provides patients with low risk therapy that affords the ability to alleviate their back pain. tTe company's Relievant’s Intracept® System delivers targeted energy into the spine and blocks the transmission of pain signals from the basivertebral nerve.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 26, 2018 | Series E | $58M | 1 | — | — | Detail |